Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Thomssen

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
The International Journal of Biological Markers|April 18, 2003
Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assayV Müller, C Thomssen, C Karakas, et al.
Journal of the National Cancer Institute|June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1F Jänicke, A Prechtl, C Thomssen, et al.
Bone Marrow Transplantation|November 1, 1988
Irradiated donor buffy coat following T cell-depleted bone marrow transplantsA Gratwohl, A Tichelli, A Würsch, et al.
British Journal of Cancer|January 1, 1997
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancerP Dettmar, N Harbeck, C Thomssen, et al.
Investigational New Drugs|August 13, 2008
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)G Schilling, M Bruweleit, N Harbeck, et al.
The International Journal of Biological Markers|April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancerA Prechtl, N Harbeck, C Thomssen, et al.
Seminars in Oncology|February 1, 1996
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancerH J Luck, C Thomssen, A duBois, et al.
Seminars in Oncology|February 1, 1997
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
Bone Marrow Transplantation|September 19, 2006
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancerN Frickhofen, W E Berdel, F Opri, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015M Untch, D Augustin, J Ettl, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
The International Journal of Biological Markers|April 18, 2003
Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assayV Müller, C Thomssen, C Karakas, et al.
Journal of the National Cancer Institute|June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1F Jänicke, A Prechtl, C Thomssen, et al.
Bone Marrow Transplantation|November 1, 1988
Irradiated donor buffy coat following T cell-depleted bone marrow transplantsA Gratwohl, A Tichelli, A Würsch, et al.
British Journal of Cancer|January 1, 1997
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancerP Dettmar, N Harbeck, C Thomssen, et al.
Investigational New Drugs|August 13, 2008
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)G Schilling, M Bruweleit, N Harbeck, et al.
The International Journal of Biological Markers|April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancerA Prechtl, N Harbeck, C Thomssen, et al.
Seminars in Oncology|February 1, 1996
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancerH J Luck, C Thomssen, A duBois, et al.
Seminars in Oncology|February 1, 1997
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancerH J Lück, C Thomssen, A du Bois, et al.
Bone Marrow Transplantation|September 19, 2006
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancerN Frickhofen, W E Berdel, F Opri, et al.
Geburtshilfe Und Frauenheilkunde|March 5, 2016
ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015M Untch, D Augustin, J Ettl, et al.
Pageof 8